Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2000;101:1552-1558

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wichter, T.
Right arrow Articles by Camici, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wichter, T.
Right arrow Articles by Camici, P. G.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Cardiomyopathy
Related Collections
Right arrow Myocardial cardiomyopathy disease
Right arrow Nuclear cardiology and PET
Right arrow Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2000;101:1552.)
© 2000 American Heart Association, Inc.


Clinical Investigation and Reports

Abnormalities of Cardiac Sympathetic Innervation in Arrhythmogenic Right Ventricular Cardiomyopathy

Quantitative Assessment of Presynaptic Norepinephrine Reuptake and Postsynaptic ß-Adrenergic Receptor Density With Positron Emission Tomography

Thomas Wichter, MD; Michael Schäfers, MD; Christopher G. Rhodes, MSc; Martin Borggrefe, MD, FESC; Hartmut Lerch, MD; Adriaan A. Lammertsma, PhD; Flemming Hermansen, MD; Otmar Schober, MD, PhD; Günter Breithardt, MD, FESC, FACC; Paolo G. Camici, MD, FESC, FACC, FRCP

From the Hospital of the Westfälische Wilhelms-University, Department of Cardiology and Angiology and Institute for Arteriosclerosis Research (T.W., M.B., G.B.) and Department of Nuclear Medicine (MS, H.L., O.S.), Münster, Germany, and the Medical Research Council-Cyclotron Unit and Imperial College School of Medicine, Hammersmith Hospital (C.G.R., A.A.L, F.H., P.G.C.), London, UK.

Correspondence to Dr Thomas Wichter, Medizinische Klinik und Poliklinik, Innere Medizin C (Kardiologie und Angiologie), Westfälische Wilhelms Universität, D-48129 Münster, Germany. E-mail wichtet{at}uni-muenster.de

Background—The frequent provocation of ventricular tachycardia by stress or catecholamines and the efficacy of antiarrhythmic drugs with antiadrenergic properties suggest an involvement of the cardiac adrenergic system in arrhythmogenesis in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). Previous studies demonstrated abnormalities of the presynaptic uptake-1 assessed by 123I-MIBG–single-photon emission computed tomography.

Methods and Results—This study investigated neuronal reuptake of norepinephrine (uptake-1) and ß-adrenergic receptor density in 8 patients with ARVC and 29 age-matched control subjects. All subjects underwent positron emission tomography with the volume of distribution (Vd) of [11C]hydroxyephedrine (11C-HED) used to assess presynaptic norepinephrine reuptake, the maximum binding capacity (Bmax) of [11C]CGP-12177 (11C-CGP-12177) to assess postsynaptic ß-adrenergic receptor density, and [15O]H2O for quantification of myocardial blood flow. Patients with ARVC demonstrated a highly significant global reduction in postsynaptic ß-adrenergic receptor density compared with that in control subjects (Bmax of 11C-CGP-12177: 5.9±1.3 vs 10.2±2.9 pmol/g tissue, P<0.0007), whereas the presynaptic uptake-1 tended toward reduction only (Vd of 11C-HED: 59.1±25.2 vs 71.0±18.8 mL/g tissue, NS). There were no differences in myocardial blood flow between the groups, and plasma norepinephrine was within normal limits in patients and control subjects.

Conclusions—The findings demonstrate a significant reduction of myocardial ß-adrenergic receptor density in patients with ARVC. This may result from a secondary downregulation after increased local synaptic norepinephrine levels caused by increased firing rates of the efferent neurons or as the result of impaired presynaptic catecholamine reuptake. These findings give new insights into the pathophysiology of arrhythmogenesis in ARVC, with potential impact on diagnostic evaluation and therapeutic management.


Key Words: cardiomyopathy • ventricular tachycardia • nervous system, autonomic • receptors, adrenergic, beta • tomography




This article has been cited by other articles:


Home page
Am. J. Respir. Cell Mol. Bio.Home page
P. Cabrales, A. G. Tsai, and M. Intaglietta
Modulation of Perfusion and Oxygenation by Red Blood Cell Oxygen Affinity during Acute Anemia
Am. J. Respir. Cell Mol. Biol., March 1, 2008; 38(3): 354 - 361.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
J. H. Caldwell, J. M. Link, W. C. Levy, J. E. Poole, and J. R. Stratton
Evidence for Pre- to Postsynaptic Mismatch of the Cardiac Sympathetic Nervous System in Ischemic Congestive Heart Failure
J. Nucl. Med., February 1, 2008; 49(2): 234 - 241.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
P. Cabrales, B. Y. S. Vazquez, A. G. Tsai, and M. Intaglietta
Microvascular and capillary perfusion following glycocalyx degradation
J Appl Physiol, June 1, 2007; 102(6): 2251 - 2259.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Kies, T. Wichter, M. Schafers, M. Paul, K. P. Schafers, L. Eckardt, L. Stegger, E. Schulze-Bahr, O. Rimoldi, G. Breithardt, et al.
Abnormal Myocardial Presynaptic Norepinephrine Recycling in Patients With Brugada Syndrome
Circulation, November 9, 2004; 110(19): 3017 - 3022.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
K. Mardon, O. Montagne, N. Elbaz, Z. Malek, A. Syrota, J.-L. Dubois-Rande, M. Meignan, and P. Merlet
Uptake-1 Carrier Downregulates in Parallel with the {beta}-Adrenergic Receptor Desensitization in Rat Hearts Chronically Exposed to High Levels of Circulating Norepinephrine: Implications for Cardiac Neuroimaging in Human Cardiomyopathies
J. Nucl. Med., September 1, 2003; 44(9): 1459 - 1466.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Furuhashi, K. Uno, K. Tsuchihashi, T. Wichter, P. Matheja, L. Eckardt, P. Kies, K. Schafers, E. Schulze-Bahr, W. Haverkamp, et al.
Myocardial Iodine-123-Metaiodobenzylguanidine (123I-MIBG) Imaging in Brugada Syndrome * Response
Circulation, September 24, 2002; 106 (13): e59 - e60.
[Full Text] [PDF]


Home page
JNMHome page
M. Pissarek, J. Ermert, G. Oesterreich, D. Bier, and H. H. Coenen
Relative Uptake, Metabolism, and {beta}-Receptor Binding of (1R,2S)-4-18F-Fluorometaraminol and 123I-MIBG in Normotensive and Spontaneously Hypertensive Rats
J. Nucl. Med., March 1, 2002; 43(3): 366 - 373.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Wichter, P. Matheja, L. Eckardt, P. Kies, K. Schafers, E. Schulze-Bahr, W. Haverkamp, M. Borggrefe, O. Schober, G. Breithardt, et al.
Cardiac Autonomic Dysfunction in Brugada Syndrome
Circulation, February 12, 2002; 105(6): 702 - 706.
[Abstract] [Full Text] [PDF]